Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab

Journal of Thoracic Oncology

Volumn 4, Issue 2, 2009, Pages 268-269

  Tanvetyanon, Tawee ^a,b   Murtagh, Ryan ^b   Bepler, Gerold ^b  

^a H Lee Moffitt Research Institute ^*  (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN HEMORRHAGE; BRAIN HERNIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN TISSUE; LETTER; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; FATALITY; LUNG TUMOR; METABOLISM; MIDDLE AGED;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CEREBRAL HEMORRHAGE; FATAL OUTCOME; HUMANS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65649120088     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318195a642     Document Type: Letter

References (5)

1. Friedlander RM. Clinical practice. Arteriovenous malformations of the brain. N Engl J Med 2007;356:2704-2712.
2. Prescribing Information. Avastin. Available at: http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf. Accessed August 28, 2008.
3. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel- carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
5. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor antagonist bevacizumab. Ann Hematol 2006;85:631-632.